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Abstract
Background: Arterial hypertension is a common disease with high prevalence in the general population. Left
ventricular hypertrophy (LVH) is an independent risk factor in arterial hypertension. Electrocardiographic indices like
the Sokolow-Lyon index (SLI) are recommended as diagnostic screening methods for LVH.
We assessed the diagnostic performance of the SLI in a cohort of a large general population.
Methods: We used electrocardiographic and echocardiographic data from the prospective, population-based
cohort study CARdio-vascular Disease, Living and Ageing in Halle (CARLA). Linear and logistic regression models
were used to assess the association of SLI with LVH. To assess the impact of the body-mass-index (BMI), we
performed interaction analyses.
Results: AUC of SLI to predict LVH was 55.3 %, sensitivity of the SLI was 5 %, specificity 97 %. We found a significant
association of SLI after covariate-adjustment with echocardiographically detected LVH (increase of left-ventricular
mass index, LVMI 7.0 g/m2 per 1 mV increase of SLI, p < 0.0001). However, this association was mainly caused by an
association of SLI with the left-ventricular internal diameter (LVIDd, increase of 0.06 cm/m2 per 1 mV increase of SLI,
p < 0.0001). In obese (BMI > 30 kg/m2) we found the strongest association with an increase of 9.2 g/m2 per 1 mV.
Conclusions: Although statistically significant, relations of SLI and echocardiographic parameters of LVH were weak
and mainly driven by the increase in LVIDd, implicating a more eccentric type of LVH in the collective. The relations
were strongest when obese subjects were taken into account. Our data do not favour the SLI as a diagnostic screening
test to identify patients at risk for LVH, especially in non-obese subjects without eccentric LVH.
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Background
Arterial hypertension is a common disease with a preva-
lence of 30–45 % in the general population in Europe [1].
A recent publication reported a prevalence of 44.2 % in the
general population in Europe with the highest prevalence
of 55.3 % in Germany [2]. There is increasing evidence of
regional differences with a higher prevalence of arterial
hypertension in the eastern part of Germany [3].
In patients with arterial hypertension, LVH initially
serves as a compensatory mechanism of the heart to deal
with the increased arterial pressure. In recent guidelines
LVH is defined as an increase in left ventricular mass
(LVM) > 115 g/m2 in men and > 95 g/m2 in women [1].
Increase of LVM is an independent risk factor in arter-
ial hypertension. In patients with arterial hypertension
without pre-existing cardiac disease and myocardial wall
thickening, the 10-year mortality rate rises up from 1 to
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6 %, with an increase in LVM of 10 % up to 24 % in case
of a concentric or eccentric hypertrophy [4]. Thus, for
patients suffering from arterial hypertension the diagno-
sis of a possibly existing LVH is of essential importance.
From the early beginnings of LVH diagnosis by means
of Chest X-ray [5], nowadays, (transthoracic) echocardi-
ography or magnetic resonance imaging (MRI) became
gold standards to assess left ventricular size and mass
[1]. Based on myocardial wall thickness, LVM can be es-
timated easily, however, echocardiography usually has to
be performed by a trained cardiologist. A transfer of the
patient to a specialist is therefore usually mandatory,
which is associated with increased costs and waiting
times for the patient. Consequently, these circumstances
weaken its value as a practical screening examination in
the general population.
For a long time, the 12-lead-electrocardiogram (ECG)
is considered a cost- and time-effective alternative in
comparison to echocardiography or MRI for detecting
LVH by using various indices. Traditionally, the 10 s-
ECG is recommended to screen patients with arterial
hypertension for LVH [1]. The most popular index was
developed and published in 1949 by Maurice Sokolow
and Thomas P. Lyon, and is calculated as the sum of the
amplitudes of the S-wave in V1 and the R-wave in V5 or
V6 (whichever is larger) [6]. In current (non-cardiologic,
general practitioner care) routine, the Sokolow-Lyon
index (SLI) by a threshold of 3.5 mV is widely used as a
measure for LVH.
All of the hypertrophy indices, in particular the SLI,
show high specificity but low sensitivity to varying de-
grees, which weakens its diagnostic value [5]. However,
most of the data reported were derived from arterial
hypertension patient collectives, while reliable data from
population-based cohort studies are still missing.
The aim of this study was to investigate the diagnostic
performance of the Sokolow-Lyon index for diagnosis of
LVH in a large cohort of the general population.
Methods
Study population
We used data from the CARdio-vascular Disease, Living
and Ageing in Halle (CARLA) study, which is a pro-
spective population-based cohort study of the general
population of the city of Halle in Saxony-Anhalt in the
Eastern part of Germany [7, 8]. The study was approved
by the Ethics Committee of the medical faculty of the
Martin-Luther-University Halle-Wittenberg and by the
State Data Privacy Commissioner of Sachsen-Anhalt.
The CARLA cohort comprises 1779 participants aged
45–83 years at baseline (812 women, 967 men). In order
to focus on the middle-aged and elderly population sub-
jects older than 45 years were considered for the study.
A multi-step recruitment strategy aimed to achieve a
high response rate. The final response rate percentage
after subtracting exclusions (individuals who were de-
ceased prior to the invitation, had moved away, or were
unable to participate due to illness) was 64 %. All data
used in this cross sectional analysis resulted from the
baseline examination of the study. The baseline examin-
ation took place between December 2002 and January
2006. The study participants underwent a detailed med-
ical examination and a standardized, computer-assisted
interview, which collected information on socio-
demographic and socioeconomic variables, behavioral,
biomedical, and psychosocial factors, medical history,
and the use of medication within the preceding 7 days.
Furthermore, anthropometric, hemodynamic (blood
pressure, ankle-brachial-index and heart rate), electro-
cardiographic and echocardiographic data were obtained
in every participant. A more comprehensive account of
the CARLA study can be found elsewhere [7].
ECG recording and processing
12-lead ECGs were recorded for 10 s after a supine rest-
ing period of at least 20 min. All ECGs were processed
by the Modular ECG Analysis System (MEANS) to ob-
tain locations and amplitudes of the QRS-complexes re-
quired for the computation of the SLI [9]. The good
performance of the MEANS has been demonstrated in
several studies [10, 11].
Echocardiographic assessment
Transthoracic Doppler echocardiographic examinations
were conducted and evaluated by specially trained and
certified physicians. All echocardiographers underwent
the same dedicated study certification procedures. The
mean intra-observer bias for the M-mode examinations
varied between 0.3 and 3.8 % (2*SD between 15.3 and
27.7 %), while the inter-observer variability ranged be-
tween 0.1 and 2.7 % (2*SD between 12.7 and 20.8 %). All
echocardiographic examinations at baseline were per-
formed using a GE ultrasound system (General Electric
Company, Fairfield, CO, USA, GE Vivid 4 and 5). To
calculate the LVM, we used the formula of the American
Society of Echocardiography (ASE-cube formula), which
is in accordance with international guidelines [1, 12,
13]. We also assessed the component variables of the
formula, which in the clinical routine often serve as
surrogate for LVH: septal wall thickness at end-diastole
(SWTd), left ventricular posterior wall thickness at
end-diastole (PWTd) and the left-ventricular internal
dimension at end-diastole (LVIDd). The measurement
of all LVM compound variables was done in the m-
mode of the parasternal long axis. The precision used
for calculation was 0.1 mm.
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Statistical methods
Results in Table 1 are given as geometric means with
their respective 95 % confidence interval (95 % CI). We
used linear regression models to assess the association
of echocardiographic components with SLI. Categoriz-
ing the SLI (cut off: 3.5 mV), we applied logistic regres-
sion models to compute odds ratios (OR) for its
association with echocardiographic parameters of LVH
(mildly impaired or above [13]). Models were adjusted
for potential confounders which were history of myo-
cardial infarction, presence of diabetes mellitus, NT
pro-BNP, low density lipoprotein, regular intake of
beta-blockers, digitalis glycosides, and anti-arrhythmic
drugs (ATC code: C01B), presence of arterial hyperten-
sion (blood pressure > 140/90 mmHg, or use of anti-
hypertensive medication), waist-to-hip ratio and sport
index. [14] Confounders were selected using directed
acyclic graphs (DAGs) as it is recommended for epi-
demiological studies [15].
Furthermore, areas under the receiver operation char-
acteristics curves (AUCs) were computed. Additionally,
we tested for interactions of LVMI and BMI (according to
the recommendations of the World Health Organization,
BMI was categorized into the classes of < 25 kg/m2 (class
I), 25–30 kg/m2 (class II), > 30 kg/m2 (class III) [16]) on a
multiplicative scale by including the corresponding inter-
action terms in the respective regression models. To re-
spect physiological relations, presented p-values of the
SLI/BMI interaction in Table 3 refer to BMI considered
on a continuous scale rather than categories (effect esti-
mates presented in the main text if statistically significant).
We assessed violations of the linearity assumption using
restricted cubic splines, which indicated that linearity was
an adequate fit to the data.
LVH was defined as a left ventricular mass index
(LVMI, LVM divided by the body surface area) above
115 g/m2 in men and above 95 g/m2 in women [1].
We performed a sensitivity analysis where we adjusted
for age and sex only in order to assess the confounding
effect of these two parameters (results presented in the
appendix).
All statistical analyses and data management were per-
formed using SAS®, Version 9.3 (SAS Inc., Cary, NC,
USA).
Results
Data of the 1779 participants of the baseline investiga-
tion were included in the statistical analysis. Baseline
data of the CARLA study, including prevalences of car-
diovascular risk factors like arterial hypertension, are
published elsewhere [8, 17].
Mean age was 63.6 years (95 % CI: 63.1–64.0). The
mean SLI was 2.2 mV (95 % CI: 2.1–2.2). In the whole
study collective, the mean systolic blood pressure (SBP)
was 142.3 mmHg (95 % CI: 141.5–143.4), while mean
diastolic blood pressure (DBP) was 84.0 mmHg (95 %
CI: 83.4–84.5). In men, mean SBP was 144.5 mmHg
(95 % CI: 143.3–145.9) and mean DBP 85.2 mmHg
(95 % CI: 84.5–85.9). In comparison, women had a mean
SBP of 140.0 mmHg (95 % CI: 138.5–141.5) and mean
DBP of 82.5 mmHg (95 % CI: 81.8–83.3). Mean LVM
and LVMI were 236.6 g (95 % CI: 232.4–240.9) and
120.0 g/m2 (95 % CI: 118.1–122.1) in men and 185.0 g
(95 % CI: 181.4–188.6) and 105.3 g/m2 (95 % CI: 103.5–
107.1) in women, respectively. Detailed descriptive data
can be found in Table 1.
For the SLI we calculated an AUC of 55.3 % (95 % CI:
52.4–58.2) to predict LVH (Fig. 1). Considering an SLI ≥
3.5 mV as threshold to define LVH, this corresponds to
a sensitivity of 5 % and a specificity of 97 %. The OR for
the association of SLI with LVH was computed to be
1.59 (95 % CI: 0.74–3.42) after considering covariates in-
dicating no statistically significant relation. The same
was true for the analyses of further echocardiographic
parameters (Table 2).
Coming to linear regression models, an increase in SLI
of 1 mV was associated with a significant increase in
Table 1 Basic characteristics
Men Women
Parameter n mean (95 % CI) n mean (95 % CI)
SLI (mV) 950 2.1 (2.1–2.1) 808 2.2 (2.2–2.3)
age (years) 967 64.0 (63.4–64.7) 812 63.0 (62.3–63.7)
QTc (ms) 950 425.0 (423.6–426.6) 808 427.8 (426.2–429.4)
LVM (g) 909 120.03 (118.1–122.1) 784 105.3 (103.5–107.1)
LVMI (g/m2) 909 236.6 (230.4–240.9) 784 185.0 (181.4–188.6)
BMI (kg/m2) 867 27.9 (27.6–28.1) 812 28.1 (27.7–28.4)
SBP (mmHg) 966 144.5 (143.3–145.8) 812 140.0 (138.5–141.5)
DBP (mmHg) 966 85.2 (84.5–85.9) 812 82.5 (81.8–83.3)
Prevalence data
n % n %
SLI 41 4.6 % 31 4.0 %
LVH 675 81.2 % 622 83.2 %
Hypertension 682 76.4 % 555 71.3 %
BMI
BMI I 202 22.6 % 212 27.3 %
BMI II 435 48.7 % 298 38.3 %
BMI III 256 28.7 % 268 34.5 %
SLI Sokolow-Lyon index, LVM left-ventricular mass, LVMI left-ventricular mass
index; BMI body-mass-index, SBP systolic blood pressure, DBP diastolic blood
pressure, QTc corrected QT-interval, 95 % CI 95 % confidence interval, LVH left
ventricular hypertrophy, BMI I BMI: <25 kg/m2 (normal), BMI II BMI: 25–30
kg/m2 (overweight), BMI III BMI: >30 kg/m2 (obese) [16]
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LVM of 4.2 g (95 % CI: 1.4–7.0, rounded values;
p = 0.0033), and after covariate adjustment of 7.0 (95 %
CI: 4.5–9.5). We found a significant association of SLI
with echocardiographic parameters only in LVIDd-index
as an increase of 0.1 cm/m2 per 1 mV. SWTd and
PWTd showed no significant correlation (Table 2).
The Table 3 shows changes in the parameters of LVH
in the different BMI classes according to the definition
of the World Health Organization [16]. We found
equally strong associations within different BMI classes I
and II (normal and overweight), but a stronger association
in class III (obese) which is supported by a significant
interaction of BMI and SLI. Thus, there was evidence that
the association of SLI with LVMI depends on BMI (mainly
driven by class III). Considering BMI as a continuous vari-
able, we found weak evidence (Table 3) of an interaction
of BMI with the SLI in their association with the left
ventricular mass index, both in the unadjusted (0.57, 95 %
CI: 0.03–1.12) and covariate adjusted analysis (0.55, 95 %
CI: 0.07–1.04).
When we adjusted for age and sex only, estimates were
not relevantly changed (see appendix).
Discussion
In our study, we found a significant association of SLI
with echocardiographically detected LVH. However, this
association was mainly caused by an association of SLI
with the LVIDd and not with the LV wall thicknesses.
Although statistically significant, relations of SLI and
echocardiographic parameters of LVH were weak. These
relations did only depend on the BMI when obese sub-
jects were taken into account. Furthermore, we found a
very high specificity, but low sensitivity of SLI to diag-
nose LVH by the common threshold of 3.5 mV. Further-
more, we found a weak association of SLI with LVM,
but there was no convincing relation with LVH. Thus,
this finding underlines that SLI is a weak parameter to
predict LVH in clinical terms and functions only weakly
to assess LVM as continuous variable.
In the CARLA study collective, a high prevalence of ar-
terial hypertension has been found [18]. In consistence, a
mean LVMI of 120.0 g/m2 in men and 105.3 g/m2 in
women indicates also a high burden of LVH. However,
considering the former recommendations for echocardio-
graphic quantification, this corresponds to a mild degree
of LVH [13].
The low sensitivity but high specificity of SLI for LVH














0.0 0.2 0.4 0.6 0.8 1.0
Fig. 1 Area under the receiver operator characteristics curve (AUC)
of 55.3 % (95 % CI: 52.4–58.2) of the SLI to predict LVH
Table 2 Linear regression of echocardiographic parameters on the Sokolow-Lyon index
Crude betaa (95 % CI) p Adjusted betaa,b (95 % CI) p
LVMI (g/m2) 4.19 (1.40–6.99) 0.0033 7.02 (4.49–9.54) <0.0001
LVIDd (cm/m2) 0.10 (0.08–0.12) <0.0001 0.06 (0.04–0.08) <0.0001
PWTd (cm) −0.01 (−0.02–0.00) 0.1533 0.01 (0.00–0.02) 0.1078
SWTd (cm) −0.01 (−0.02–0.00) 0.1435 0.01 (0.00–0.02) 0.0927
Dichotomized outcome for impaired
echocardiographic LVH parameters
[13] (odds ratios)
LVMI 1.37 (0.67–2.79) 0.3892 1.59 (0.74–3.42) 0.233
LVIDd 1.93 (0.81–4.61) 0.1379 1.24 (0.48–3.16) 0.6572
PWTd 2 (0.48–8.29) 0.341 2.62 (0.59–11.59) 0.2041
SWTd 2.25 (0.54–9.32) 0.2633 2.66 (0.6–11.81) 0.1993
SLI Sokolow-Lyon index, LVMI left ventricular mass index, LVIDd left-ventricular internal diameter at end-diastole index, PWTd left-ventricular posterior wall
thickness at end-diastole, SWTd septal wall thickness at end-diastole, 95 % CI 95 % confidence interval
aadjusted for sex, sport index, smoking status, NT-pro BNP, low density lipoprotein, arterial hypertension, waist-to-hip ratio, diabetes mellitus, regular intake of
antiarrhythmic medication, beta blockers and digitalis glycosides
bBeta gives the increase of the respective echocardiographic parameter per mV increase of the SLI
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regression model, we found a significant relationship be-
tween the SLI and the LVMI (and LVIDd), although the
overall relation indicated only a minor effect.
Several publications suggested a negative influence of
obesity on the predictive value of the SLI [21–25]. In
our study, we found significant elevations of LVMI with
increasing SLI in all BMI classes, whereby the strongest
association was observed in BMI class III. However, like in
the whole sample, this association appeared to be mainly
driven by the association of SLI and LVIDd - implicating,
that SLI is primarily useful as a tool to diagnose a more
eccentric type of LVH in our collective, especially in obese
subjects. This might support recent findings which also
implicate a higher prevalence of eccentric LVH prevailing
over concentric LVH in obese patients, which might be
explained by the elevated cardiac output and increased
plasma volume in those patients [26].
The poor performance of the SLI has already been re-
ported in several publications over last decades, but pre-
dominantly in hypertensive or old patient collectives [19,
20, 27–29]. In our study, we found similar results in a large
general population. However, in the CARLA study collect-
ive there is a high prevalence of arterial hypertension [18].
This study has some limitations. At first, this was a
retrospective analysis of prospective obtained data. All pa-
tients received a transthoracical echocardiography, which
is the recommended examination for detecting LVH in re-
cent guidelines [1]. Although it has to be stated, that in
obese patients quality of echocardiographic assessments
often can be poor. Furthermore, in the CARLA collective
a high prevalence of arterial hypertension and also LVH
(Table 1) was found and, thus, can be regarded as a select-
ive high risk population, which is likely not representative
for the general population in other regions.
Conclusions
In conclusion, the Sokolow-Lyon index is not suitable
as a diagnostic screening test to identify patients at risk
for LVH, in particular in non-obese subjects without
eccentric LVH. This is consistent with the recom-
mendation of Ang and Lang from 2008 to take into
consideration the ECG-findings, but only additive to a
patient’s risk factors and results of 24-hour -blood pres-
sure monitoring, to lead the right patient to echocardi-
ography [30].
Appendix
Table 3 Linear regression of echocardiographic parameters on the Sokolow-Lyon index within considered BMI categories, and
respective interaction analyses
BMI (kg/m2) Crude betaa (95 % CI) p p (interaction)* Adjusted betaa,b (95 % CI) p p (interaction)*
LVMI (g/m2) <25 6.34 (1.58, 11.10) 0.0092 4.79 (0.47, 9.11) 0.0041
25–29.9 6.09 (1.86, 10.33) 0.0049 0.0389 5.51 (1.75, 9.27) 0.001 0.0244
≥30 9.55 (3.81, 15.30) 0.0012 9.24 (3.75, 14.73) 0.001
LVIDd (cm/m2) <25 0.05 (0.00, 0.09) 0.0384 0.03 (−0.01, 0.07) 0.1306
25–29.9 0.10 (0.06, 0.13) <0.0001 0.3948 0.08 (0.05, 0.12) <0.0001 0.1280
≥30 0.08 (0.04, 0.12) 0.0002 0.07 (0.02, 0.11) 0.0031
PWTd (cm) <25 0.02 (−0.01, 0.04) 0.2255 0.01 (−0.01, 0.03) 0.4774
25–29.9 0.00 (−0.02, 0.02) 0.9225 0.3672 −0.01 (−0.03, 0.01) 0.5528 0.4426
≥30 0.02 (−0.01, 0.04) 0.2604 0.02 (−0.01, 0.04) 0.2478
SWTd (cm) <25 0.01 (−0.01, 0.04) 0.3217 0.01 (−0.01, 0.03) 0.4411
25–29.9 0.01 (−0.02, 0.03) 0.624 0.6835 0.00 (−0.02, 0.02) 0.8048 0.9081
≥30 0.01 (−0.02, 0.03) 0.4979 0.01 (−0.02, 0.03) 0.5193
SLI Sokolow-Lyon index, LVMI left-ventricular mass index, LVIDd left-ventricular internal diameter at end-diastole index, PWTd left-ventricular posterior wall
thickness at end-diastole, SWTd septal wall thickness at end-diastole, 95 % CI 95 % confidence interval
*p-value of the multiplicative interaction of the SLI with considered BMI classes
aadjusted for sex, sport index, smoking status, NT-pro BNP, low density lipoprotein, arterial hypertension, waist-to-hip ratio, diabetes mellitus, regular intake of
antiarrhythmic medication, beta blockers and digitalis glycosides
bBeta gives the increase of the respective echocardiographic parameter per mV increase of the SLI
Table 4 Linear regression of echocardiographic parameters on
the Sokolow-Lyon index
Adjusted betaa,b (95 % CI) p
LVMI (g/m2) 5.35 (2.75–7.95) <0.0001
LVIDd (cm/m2) 0.10 (0.08–0.12) < 0.0001
PWTd (cm) 0.00 (−0.02–0.01) 0.4503
SWTd (cm) 0.00 (−0.02–0.01) 0.4804
LVMI left ventricular mass index, LVIDd left-ventricular internal diameter
at end-diastole index, PWTd left-ventricular posterior wall thickness at
end-diastole, SWTd septal wall thickness at end-diastole, 95 % CI 95 %
confidence interval
aadjusted for age and sex only
bBeta gives the increase of the respective echocardiographic parameter per
mV increase of the SLI
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